It has been proven that during RVO, vascular endothelial growth factor (VEGF) is the main cytokine inducing ischemia and neovascularization; therefore, intravitreal anti-VEGF in the event of macular edema following retinal vein occlusion is the first line of treatment [1]. This evidence concerns the gene VEGFA and macular retinal edema.